Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 17/20 | 0.66 |
| ▸ | DDB1 | Q16531 | 12/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.61 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.61 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | IKZF1 | Q13422 | 2/20 | 0.53 |
| ▸ | IKZF2 | Q9UKS7 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22720830 | 0.92 | CRBN (0.65) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL30718203 | 0.92 | CRBN (0.65) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL20076083 | 0.91 | CRBN (0.63) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL29426673 | 0.91 | CRBN (0.63) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| Hydrochloric Acid SCHEMBL23250103 | 0.90 | CRBN (0.62) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| Hydrochloric Acid SCHEMBL29874019 | 0.90 | CRBN (0.62) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL29058466 | 0.89 | CRBN (0.65) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL30488958 | 0.89 | CRBN (0.65) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL20046055 | 0.89 | CRBN (0.65) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL31335123 | 0.89 | CRBN (0.58) | CRBNDDB1ALDH1A1CHRM2OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11787800-B2 | BRD9 degraders and uses thereof | FOGHORN THERAPEUTICS INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230142883-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-11 | — | — | US | disclosed |
| US-11535606-B2 | Substituted quinoline-8-carbonitrile derivatives with androgen receptor degradation activity and uses thereof | ACCUTAR BIOTECHNOLOGY INC. (US) | 2022-12-27 | — | — | US | disclosed |
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | MAPT, VHL, CRBN | CRBN 3/4885DDB1 433/4885ALDH1A1 3804/4885 |
| US-11535606-B2 | Substituted quinoline-8-carbonitrile derivatives with androgen receptor degradation activity and uses thereof | AR, NR5A1, ESRRA | CRBN 360/4885DDB1 897/4885ALDH1A1 290/4885 |
| US-20230142883-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | CRBN 74/4885DDB1 706/4885ALDH1A1 1358/4885 |
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | CRBN, VHL, UBQLN2 | CRBN 1/4885DDB1 473/4885ALDH1A1 4249/4885 |
| US-11787800-B2 | BRD9 degraders and uses thereof | BRD9, BRWD1, BRD2 | CRBN 60/4885DDB1 895/4885ALDH1A1 3268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.